~~<i id='DD97451839'><strike id='DD97451839'><tt id='DD97451839'><pre id='DD97451839'></pre></tt></strike></i>~~

Home» knowledge» focus

focus

author：hotspot 2025-09-28 03:49:28 Page View：778

Novo Nordisk headquarters -- health coverage from STAT — LISELOTTE SABROE/Scanpix/AFP via Getty Images

LONDON — Novo Nordisk said Monday it would acquire the German firm Cardior Pharmaceuticals in a deal worth up to $1.1 billion, picking up additional drug candidates for its pipeline of cardiometabolic medicines.

Cardior focuses on targeting RNA to address the root causes of heart disease. Its lead candidate, known CDR132L, is in Phase 2 development as a treatment for health failure.

The companies did not disclose how much Novo was paying upfront for Cardior and how much would be based on future milestones being achieved. The deal is expected to close in the second quarter.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Pfizer's Covid pill remains 89% effective in final analysis, company says
Next article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

explore

Peter Hotez and the public health issue of online harassment

AdobeFather’sDayweekendwasanythingbutcalmonTwitter,whicheruptedasvaccineexpertPeterHotezwaschallenge

Abortion clinic in Cancun will cater to Americans

AerialviewofCancun,Mexico,whereanewabortionclinicexpectstodrawAmericantravelers.DANIELSLIM/AFPviaGet

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

1:19Ademonstratorrunsonthethirdnightofprotestssparkedbythefatalpoliceshootingofa17-year-olddriverint

AstraZeneca CEO says participant had neurological symptoms, could be discharged today

PascalSoriot,thechiefexecutiveofficerofAstraZeneca.WinMcNamee/GettyImagesTheparticipantwhotriggereda